On improving the safety of new direct acting oral anticoagulants
Abstract
One of the main causes of death and disability in the world are the thrombotic complications. Using of anticoagulants is the effective method of preventing of these life-threatening conditions. However, the use of anticoagulants involves a significant risk of the bleeding. Safety of anticoagulants predominately are determined by the availability of specific antidotes. Until now new oral directly acting anticoagulants do not have any specific antagonists. Idarutsizumab is the dagibatran-specific antagonist which increases its safety.
About the Authors
N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
O. E. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Zadionchenco, VS. Instead of warfarin in the treatment and prevention of thromboembolic. Russian Medical Journal. 2011; 26: 1648–1657.
2. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke, 2006; 37(1): 256–262.
3. Ellis, F. Unger Atrial fibrillation and new oral anticoagulant drugs. [Electronic resource]: URL: http://www.fda.gov/Drugs/NewsEvents/ucm405148.htm (Cited: 28.03.2016).
4. Donati, M. The dabigatran case: the importance of transparency [Electronic resource]. URL: http://www.pharmaco-vigilance.eu/content/dabigatran-caseimportance-transparency (Cited: 29.03.2016).
5. Aguilar MI, Brott TG. Update in Intracerebral Hemorrhage. The Neurohospitalist. 2011; 1(3): 148–159.
6. Cohen, D. Dabigatran: how the drug company withheld important analyses [Electronic resource]. URL: http://www.bmj.com/bmj/section-pdf/761385/5 (Cited: 28.03.2016).
7. Neale, Ò. Pradaxa Safety as Expected in New FDA Study [Electronic resource]. URL: http://www.medpagetoday.com/Cardiology/Arrhythmias/45758 (Cited: 28.03.2016).
8. As the benefits and safety of Pradaxa® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa® to help more patients [Electronic resource]. URL: https://www.boehringer-ingelheim.com/news/news_releases/press_releases/ 2014/15_may_2014_dabigatranetexilate.html (Cited: 28.03.2016).
9. Avdeeva ZhI, Soldatov AA, Alpatova NA et al. Preparationsof next generation monoclonal antibodies (issues and prospects). Biopreparation (Biopharmaceuticals) 2015; (1): 21–35.
10. FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa: Praxbind approved for specific emergency situations [press release]. [Electronic resource]. URL:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm. (Cited: 29.03.2016).
Review
For citations:
Velts N.Yu., Darmostukova M.A., Kazakov A.S., Bukatina T.M., Zhuravleva O.E., Alyautdin R.N., Romanov B.K. On improving the safety of new direct acting oral anticoagulants. Safety and Risk of Pharmacotherapy. 2016;(2):28-32. (In Russ.)
Views:
1099
Email this article 